image: In June 2024, a landmark Alzheimer's research paper was retracted due to fraud allegations. Did we waste billions of dollars and thousands of hours of scientists’ time? Maybe not. There are now two potentially helpful drugs on the market targeting the subject of the paper: amyloid beta. This video breaks down the amyloid-beta hypothesis, the fraud itself and where we go from here.
Credit: The American Chemical Society
WASHINGTON, Aug. 26, 2024 — In June 2024, a landmark Alzheimer's research paper was retracted due to fraud allegations. Did we waste billions of dollars and thousands of hours of scientists’ time? Maybe not. There are now two potentially helpful drugs on the market targeting the subject of the paper: amyloid beta. This video breaks down the amyloid-beta hypothesis, the fraud itself and where we go from here.
Reactions is a video series produced by the American Chemical Society and PBS Digital Studios. Subscribe to Reactions and follow us on X, formerly Twitter @ACSReactions.
The American Chemical Society (ACS) is a nonprofit organization chartered by the U.S. Congress. ACS’ mission is to advance the broader chemistry enterprise and its practitioners for the benefit of Earth and all its people. The Society is a global leader in promoting excellence in science education and providing access to chemistry-related information and research through its multiple research solutions, peer-reviewed journals, scientific conferences, eBooks and weekly news periodical Chemical & Engineering News. ACS journals are among the most cited, most trusted and most read within the scientific literature; however, ACS itself does not conduct chemical research. As a leader in scientific information solutions, its CAS division partners with global innovators to accelerate breakthroughs by curating, connecting and analyzing the world’s scientific knowledge. ACS’ main offices are in Washington, D.C., and Columbus, Ohio.
To automatically receive news releases from the American Chemical Society, contact newsroom@acs.org.
Follow us: Twitter | Facebook | Instagram